BDC steps up its defence-sector footprint with investments in semiconductors and space tech and a new strategic partnership

MONTRÉAL, Jan. 27, 2026 (GLOBE NEWSWIRE) — BDC is announcing the first two investments in Canadian dual-use innovators, following the launch of its Defence Platform in December: Irreversible (QC) – A semiconductor startup developing AI chips for next-generation computing. BDC participated in Irreversible's pre-seed round, led by Quantacet with participation from Frostbite Capital and Tofino […]

Distractions Down, Confidence Up: New AI Colonoscopy Software Delivers More Transparent Polyp Detection

OSLO, Norway, Jan. 27, 2026 (GLOBE NEWSWIRE) — Augere Medical (“Augere”), a European pioneer in AI-assisted colonoscopy, today announced the commercial release of its next-generation software module 1.9 for real-time polyp detection on colonoscopy systems. The release increases transparency of AI behaviour using the unique real-time Confidence Indicator, giving endoscopists more control over how AI-support

Alrajhi Medicine to Digitize its Healthcare Operations with Oracle to Foster Better Patient and Staff Experiences

Adopts Oracle Health Foundation EHR and Oracle Fusion Cloud Applications to increase efficiency and drive growth Alrajhi Medicine, a fast-growing private healthcare network operating multi-specialty hospitals and medical centers in Saudi Arabia, is teaming with Oracle to power its next-generation healthcare operations. By implementing Oracle Health Foundation electronic health record (EHR) and Oracle Fusion Cloud

EPG Completes Nearly US$100 Million Series B Financing, Bolsters Global Data Center Delivery Capabilities

EPG recently completed its Series B financing, raising nearly US$100 million. The round was co-led by international investment firms Forebright and Silicon Peak, with participation from GL Ventures, NRL Capital, YF Capital, and Rockets Capital. In 2025, EPG also completed its Series A and A+ rounds, raising tens of millions of U.S. dollars from investors

EPG Completes Nearly US$100 Million Series B Financing, Bolsters Global Data Center Delivery Capabilities

EPG recently completed its Series B financing, raising nearly US$100 million. The round was co-led by international investment firms Forebright and Silicon Peak, with participation from GL Ventures, NRL Capital, YF Capital, and Rockets Capital. In 2025, EPG also completed its Series A and A+ rounds, raising tens of millions of U.S. dollars from investors

Current geopolitical tensions are putting pressure on the internal security of European organisations

84% of European high-risk profile organisations do not feel well equipped to detect and handle insider incidents, according to the Insider Risk Trend Report 2026 published today by insider risk advisory firm Signpost Six. European organisations are under increasing pressure from geopolitical developments but seem to pay insufficient attention to security risks that arise from

Distractions Down, Confidence Up: New AI Colonoscopy Software Delivers More Transparent Polyp Detection

Distractions Down, Confidence Up: New AI Colonoscopy Software Delivers More Transparent Polyp Detection GlobeNewswire January 27, 2026 OSLO, Norway, Jan. 27, 2026 (GLOBE NEWSWIRE) — Augere Medical (“Augere”), a European pioneer in AI-assisted colonoscopy, today announced the commercial release of its next-generation software module 1.9 for real-time polyp detection on colonoscopy systems. The release increases

BDC steps up its defence-sector footprint with investments in semiconductors and space tech and a new strategic partnership

BDC steps up its defence-sector footprint with investments in semiconductors and space tech and a new strategic partnership BDC invests in semiconductor company Irreversible and aerospace company Canada Rocket Company and becomes first partner of Creative Destruction Lab (CDL)'s global Defence program GlobeNewswire January 27, 2026 MONTRÉAL, Jan. 27, 2026 (GLOBE NEWSWIRE) — BDC is

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million

Scroll to Top